Contact Us
Drug Search Results
More Filters [+]

Rocuronium bromide

Alternative Names: rocuronium bromide, org 9426, zemuron, eslax
Latest Update: 2024-11-16
Latest Update Note: Clinical Trial Update

Product Description

Rocuronium is a new nondepolarizing neuromuscular blocking drug. Its onset of action is comparable to that of succinylcholine, with good-to-excellent intubating conditions possible 1 minute after doses two times the ED95 (600 micrograms/kg). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/8122487/)

Mechanisms of Action: nAChR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Anastesia Related

Known Adverse Events: Hypertension | Hypotension

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rocuronium bromide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

09/02/2023

News Article

 Understanding Rocuronium Bromide Market Size and Industry Revenue from 2023 to 2030 with growing 11.7% CAGR

09/02/2023

News Article

 The BabyNes Machine market analysis study delivers accurate data on market size, share, volume, and possible growth trajectories, with an anticipated CAGR value of 4.4% from 2023 to 2030.

09/02/2023

News Article

 This report evaluates the demand for the BabyNes Capsule market, key suppliers, and major geographic regions from 2023 to 2030 and forecasts a CAGR of 10.9%.

09/02/2023

News Article

 This report provides a comprehensive analysis of the Salinomycin Premix market's current state and future growth potential, with a projected CAGR of 13.1% over the forecast period 2023 to 2030.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions